CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activation
Cited by 39
Related Papers
Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint
|Journal of Experimental & Clinical Cancer Research|2018|56
Characterization and validation of potential therapeutic targets based on the molecular signature of patient-derived xenografts in gastric cancer
|Journal of Hematology & Oncology|2018|44